Janux Therapeutics, INC

Janux Therapeutics stockholders re-elected Class II directors and ratified the appointment of Ernst & Young LLP.

Janux Therapeutics reported Q1 2026 financial results, highlighting progress in its prostate cancer franchise with JANX007 and JANX014, and announced a $35 million milestone payment from a Bristol Myers Squibb collaboration.

Janux Therapeutics reclassified director Eric Dobmeier from Class III to Class II to balance board membership.

Janux Therapeutics announced its full year 2025 financial results and business highlights, showcasing continued clinical execution and a new collaboration with Bristol Myers Squibb.

Janux Therapeutics announced an exclusive worldwide license and collaboration agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors, potentially worth up to $800 million.

Janux Therapeutics announced its third quarter 2025 financial results, highlighting ongoing clinical trial enrollment for JANX007 and JANX008 and a strong cash position.

Janux Therapeutics filed its Q1 2026 10-Q, detailing a net loss of $24.4 million and significant progress in its collaboration with Bristol-Myers Squibb.

Janux Therapeutics reported a net loss of $24.3 million for Q3 2025, driven by increased R&D, while advancing its TRACTr and ARM platforms and securing a $10 million Merck milestone.

Janux Therapeutics reported a significant increase in net loss driven by higher research and development expenses, while maintaining a strong cash position to fund its clinical-stage immunotherapy pipeline.

Janux Therapeutics reports a net loss of $23.5 million for Q1 2025, alongside updates on its clinical programs JANX007 and JANX008.

Janux Therapeutics' Q3 2024 report reveals increased collaboration revenue and strategic investments, alongside ongoing clinical development of its TRACTr platform.

Janux Therapeutics reports a significant increase in collaboration revenue and a reduced net loss for the second quarter of 2024, driven by a milestone achievement in its Merck partnership.

Janux Therapeutics' 2025 annual report highlights significant clinical advancements for its TRACTr and ARM platforms, alongside new and ongoing strategic collaborations.

Janux Therapeutics' 10-K filing highlights encouraging clinical trial results for its lead candidates and details its strategic plans for future growth in the immuno-oncology space.

Janux Therapeutics announces positive interim clinical data for its TRACTr platform, showing anti-tumor activity and manageable safety profiles in early trials.

David Alan Campbell, President and CEO and a Director of Janux Therapeutics, Inc., reported a transaction in 123,840 shares of common stock on July 31, 2026.

Janux Therapeutics President and CEO David Alan Campbell acquired 7,000 shares of common stock.

RA Capital Management reports a grant of restricted stock units and stock options to Dr. Jake Simson for his service on the Janux Therapeutics board.

Director Jake Simson was granted 5,500 restricted stock units and 15,500 stock options as part of standard compensation.

Janux Therapeutics director Winston Kung was granted 5,500 restricted stock units and 15,500 stock options on June 11, 2026.

Director Natasha Hernday was granted 5,500 restricted stock units and 15,500 stock options by Janux Therapeutics.

Janux Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, detailing proposals for director elections, auditor ratification, and executive compensation.

Janux Therapeutics will hold its annual stockholders meeting on June 11, 2025, to vote on director elections, auditor ratification, executive compensation, and other business.

Janux Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to vote on director elections, auditor ratification, executive compensation, and the frequency of say-on-pay votes.

Janux Therapeutics amends and restates its non-employee director compensation policy, effective immediately, with changes to equity awards.

Janux Therapeutics will hold its annual stockholders meeting virtually on June 26, 2024, to elect directors and ratify the selection of Ernst & Young LLP as its independent accounting firm.

Janux Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 26, 2024, to elect directors and ratify the selection of its independent accounting firm.

RA Capital Management and its affiliates have increased their beneficial ownership in Janux Therapeutics, Inc. to 19.9% through recent open market purchases.

Janus Henderson Group plc has reported a beneficial ownership of 6.9% in Janux Therapeutics, Inc., holding 4,196,409 shares as of March 31, 2026.

State Street Corporation has reported a beneficial ownership of 4.1% in Janux Therapeutics Inc. as of March 31, 2026.

FMR LLC has reported beneficial ownership of 4.2% of Janux Therapeutics Inc.'s common stock as of March 31, 2026.

Point72 Asset Management, L.P., along with affiliated entities and Steven A. Cohen, has reported beneficial ownership of 5.0% of Janux Therapeutics, Inc. common stock as of April 28, 2026.

Point72 Asset Management, L.P., along with affiliated entities and Steven A. Cohen, has reported beneficial ownership of 5.0% of Janux Therapeutics, Inc. common stock as of April 28, 2026.

State Street Corporation has reported a 6.4% beneficial ownership stake in Janux Therapeutics Inc. common stock as of December 31, 2025.